Currently, therapeutic strategies for breast cancer depend essentially on the classification of the breast cancer subtypes, viz., HR+/HER2−, HER2+ and triple-negative (HR−/HER2−) [68]. The gene discussed is ERBB2; the disease is breast carcinoma.